287 related articles for article (PubMed ID: 22182771)
21. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo.
Sawant RR; Torchilin VP
Int J Pharm; 2009 Jun; 374(1-2):114-8. PubMed ID: 19446767
[TBL] [Abstract][Full Text] [Related]
22. Surface-modified cationic liposomes with a matrix metalloproteinase-degradable polyethylene glycol derivative improved doxorubicin delivery in murine colon cancer.
Askarizadeh A; Mashreghi M; Mirhadi E; Mehrabian A; Heravi Shargh V; Badiee A; Alavizadeh SH; Arabi L; Kamali H; Jaafari MR
J Liposome Res; 2024 Jun; 34(2):221-238. PubMed ID: 37647288
[TBL] [Abstract][Full Text] [Related]
23. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.
Elbayoumi TA; Pabba S; Roby A; Torchilin VP
J Liposome Res; 2007; 17(1):1-14. PubMed ID: 17454399
[TBL] [Abstract][Full Text] [Related]
24. pH-Sensitive nanoparticles as smart carriers for selective intracellular drug delivery to tumor.
Li XX; Chen J; Shen JM; Zhuang R; Zhang SQ; Zhu ZY; Ma JB
Int J Pharm; 2018 Jul; 545(1-2):274-285. PubMed ID: 29733971
[TBL] [Abstract][Full Text] [Related]
25. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
[TBL] [Abstract][Full Text] [Related]
26. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors.
Sethuraman VA; Bae YH
J Control Release; 2007 Apr; 118(2):216-24. PubMed ID: 17239466
[TBL] [Abstract][Full Text] [Related]
27. [Preparation and in vitro evaluation of pH-sensitive TAT peptide conjugated micelles].
Chen W; Jin MJ; Gao ZG; Wang LP; Piao HF
Yao Xue Xue Bao; 2011 May; 46(5):599-604. PubMed ID: 21800551
[TBL] [Abstract][Full Text] [Related]
28. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation.
Zhao P; Wang H; Yu M; Cao S; Zhang F; Chang J; Niu R
Pharm Res; 2010 Sep; 27(9):1914-26. PubMed ID: 20582454
[TBL] [Abstract][Full Text] [Related]
29. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
30. Tumor targeting using anti-her2 immunoliposomes.
Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC
J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487
[TBL] [Abstract][Full Text] [Related]
31. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes.
Kuai R; Yuan W; Qin Y; Chen H; Tang J; Yuan M; Zhang Z; He Q
Mol Pharm; 2010 Oct; 7(5):1816-26. PubMed ID: 20701288
[TBL] [Abstract][Full Text] [Related]
32. Smart pH- and reduction-dual-responsive folate-PEG-coated polymeric lipid vesicles for tumor-triggered targeted drug delivery.
Wang S; Wang H; Liu Z; Wang L; Wang X; Su L; Chang J
Nanoscale; 2014 Jul; 6(13):7635-42. PubMed ID: 24898341
[TBL] [Abstract][Full Text] [Related]
33. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
ElBayoumi TA; Torchilin VP
Clin Cancer Res; 2009 Mar; 15(6):1973-80. PubMed ID: 19276264
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.
Gupta B; Torchilin VP
Cancer Immunol Immunother; 2007 Aug; 56(8):1215-23. PubMed ID: 17219149
[TBL] [Abstract][Full Text] [Related]
35. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo.
Biswas S; Dodwadkar NS; Deshpande PP; Torchilin VP
J Control Release; 2012 May; 159(3):393-402. PubMed ID: 22286008
[TBL] [Abstract][Full Text] [Related]
36. Enhanced antitumor activity of different double arms polyethyleneglycol-modified liposomal doxorubicin.
Sugiyama I; Sadzuka Y
Int J Pharm; 2013 Jan; 441(1-2):279-84. PubMed ID: 23194885
[TBL] [Abstract][Full Text] [Related]
37. Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery.
Prabaharan M; Grailer JJ; Pilla S; Steeber DA; Gong S
Biomaterials; 2009 Oct; 30(29):5757-66. PubMed ID: 19643472
[TBL] [Abstract][Full Text] [Related]
38. pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Bersani S; Vila-Caballer M; Brazzale C; Barattin M; Salmaso S
Eur J Pharm Biopharm; 2014 Nov; 88(3):670-82. PubMed ID: 25157908
[TBL] [Abstract][Full Text] [Related]
39. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
[TBL] [Abstract][Full Text] [Related]
40. HIV TAT peptide modifies the distribution of DNA nanolipoparticles following convection-enhanced delivery.
MacKay JA; Li W; Huang Z; Dy EE; Huynh G; Tihan T; Collins R; Deen DF; Szoka FC
Mol Ther; 2008 May; 16(5):893-900. PubMed ID: 18388927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
